Clinical Trials on Glucose Infusion in Spain

Total 668 results

AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Type 2 Diabetes

United States, Bulgaria, Russian Federation, United Kingdom, Hungary, Romania, Finland, Canada, Austria, Germany, Netherlands, Slovakia, Spain
Sanofi

Completed

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes (PRESCHOOL)

Type 1 Diabetes Mellitus

United States, Austria, Brazil, Chile, Czech Republic, Germany, Hungary, India, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Turkey
Eli Lilly and Company

Completed

A Study in Participants With Type 2 Diabetes Mellitus (IMAGINE 4)

Diabetes Mellitus, Type 2

Israel, Italy, Russian Federation, Turkey, Japan, Czechia, Spain, United Kingdom, United States, Australia, Hungary, Puerto Rico, Mexico, Austria, Germany, Denmark, Croatia, Greece, Romania, Taiwan, Brazil, Netherlands, Poland, Lithuania and more
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control | High HbA1c Level

Czech Republic, Poland, Spain, Germany, Canada, Slovakia
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
GlaxoSmithKline

Completed

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Diabetes Mellitus, Type 2

United States, Germany, Taiwan, South Africa, Korea, Republic of, Spain, Brazil, India, Peru, Philippines, United Kingdom, Hong Kong, France, Mexico
Gan and Lee Pharmaceuticals, USA

Withdrawn

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro (GENTL 1)

Diabetes Mellitus, Type 1

United States, Spain, Hungary, Poland, Germany, Czechia
GlaxoSmithKline

Completed

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

Diabetes Mellitus, Type 2

United States, Peru, Israel, Australia, United Kingdom, Korea, Republic of, Spain, Philippines
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Israel, Poland, United Kingdom, Denmark, Spain, France, Austria, Norway, Russian Federation, Canada, Croatia, Argentina, South Africa, Australia, Ireland, Brazil, Finland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Diamyd Therapeutics AB

Terminated

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

Type 1 Diabetes Mellitus

France, Germany, Finland, Italy, Netherlands, Slovenia, Spain, Sweden, United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Obesity | Diabetes Mellitus, Type 2

United States, Belgium, Bulgaria, Colombia, Czech Republic, Finland, France, Germany, Guatemala, Mexico, Peru, Russian Federation, Spain, Ukraine
Novo Nordisk A/S

Completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Puerto Rico, United Kingdom, Ireland, Germany, Slovenia, Canada, France, Italy, Spain, Netherlands, Slovakia, Romania, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together (LEAD-2)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia, India, Italy, Russian Federation, Spain, Denmark, United Kingdom, Sweden, Belgium, Ireland, Argentina, Hungary, Norway, South Africa, Germany, Croatia, Netherlands, Bulgaria, Australia, Romania
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Pfizer

Terminated

A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

Spain, Canada, France, Greece, Portugal, Sweden, Turkey
Novo Nordisk A/S

Completed

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, United Kingdom, Canada, Denmark, Spain, Netherlands, Malaysia, Taiwan, Germany, Poland, Turkey, Argentina, South Africa, Romania, Thailand, Algeria, Brazil
Novo Nordisk A/S

Completed

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Italy, Puerto Rico, Spain, United Kingdom, Netherlands, Belgium, Germany, France, Canada
Eli Lilly and Company

Completed

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (AWARD-11)

Diabetes Mellitus, Type 2

Russian Federation, United States, Spain, Italy, Puerto Rico, Canada, Poland, Austria, Hungary, Israel, Greece, Taiwan, Argentina, Romania, Mexico, Slovakia
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Russian Federation, Spain, United Kingdom, Austria, Belgium, Mexico, Sweden, Israel, Taiwan, Hungary, Malaysia, Serbia, Turkey, Denmark, Greece, Thailand, North Macedonia, Norway, Portugal, Germany, Romania and more
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Bristol-Myers Squibb

Completed

PPAR-COMBO With Sulfonylurea

Metabolics Diabetes Nos

United States, Spain, Argentina, Brazil, Germany, Mexico, Peru, Puerto Rico, Australia, Canada, Russian Federation, United Kingdom, France, Italy, Netherlands
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Diabetes Mellitus Type 2

Spain, Italy, United States, Germany, United Kingdom, Russian Federation, Canada, Poland, Puerto Rico, Macedonia, The Former Yugoslav Republic of
AstraZeneca
Eli Lilly and Company

Completed

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Type 2 Diabetes Mellitus

United States, Czech Republic, France, Korea, Republic of, Russian Federation, Spain, Mexico, Australia, Belgium, Denmark, Germany, Hungary, Netherlands, Puerto Rico, Greece, Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin (GENERATION)

Type 2 Diabetes Mellitus

Sweden, Italy, United Kingdom, Finland, Norway, Mexico, Austria, Denmark, Germany, Hungary, Greece, France, Spain
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
GlaxoSmithKline
Juvenile Diabetes Research Foundation

Completed

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1 (DEFEND-1)

Diabetes Mellitus, Type 1

United States, Finland, Sweden, Italy, Spain, United Kingdom, Germany, Canada, Denmark
Novo Nordisk A/S

Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, Poland, Russian Federation, Spain, Canada, Denmark, Taiwan, Malaysia, United Kingdom, Turkey, Germany, Bulgaria, Argentina, Australia, Thailand, Algeria, Brazil
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom
Eli Lilly and Company

Completed

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (IOOV)

Diabetes Mellitus, Type 2

United States, Canada, India, Puerto Rico, Australia, Spain, Netherlands, Hungary, Brazil, Greece, Romania, Argentina
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
AstraZeneca
Bristol-Myers Squibb

Completed

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Diabetes Mellitus, Type 2

Australia, United States, Italy, Argentina, Canada, Mexico, India, Peru, Spain, Denmark, France, Singapore, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Czech Republic, Italy, Poland, Spain, United Kingdom, Germany, Hungary, Finland, Mexico, Austria, France, Israel, Switzerland, Ireland
GlaxoSmithKline

Completed

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Peru, Spain, United Kingdom, India, Philippines, Russian Federation, Hong Kong
Pfizer
Sanofi

Completed

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

Diabetes Mellitus

United States, Canada, Spain, Italy, United Kingdom, Germany, France
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (SORELLA1)

Type 1 Diabetes Mellitus

Japan, Spain, Germany, United States, France, Hungary, Poland, Russian Federation
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
Andromeda Biotech Ltd.

Completed

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults (DIA-AID2)

Type 1 Diabetes Mellitus

United States, Russian Federation, Israel, Spain, Lithuania, Germany, Austria, Belarus, Canada, Czech Republic, Finland, Hungary, Italy, Poland
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Type 2 Diabetes

United States, Spain, Taiwan, Japan, Poland, Argentina, Hungary, Puerto Rico, Korea, Republic of, Slovakia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Diabetes Mellitus, Type 1

United States, Spain, Taiwan, Belgium, United Kingdom, Germany, Canada, Australia, Finland, Netherlands, Poland, France, Denmark, Norway, Sweden, Austria, Czechia
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (ADJUNCT TWO™)

Diabetes | Diabetes Mellitus, Type 1

United States, Italy, Canada, Denmark, Finland, Spain, Netherlands, Austria, Sweden, Belgium, France, Bulgaria, South Africa
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Diabetes Mellitus Type 2

United States, France, Switzerland, Germany, South Africa, Korea, Republic of, Puerto Rico, Canada, Taiwan, Spain, Poland, Slovakia, Thailand, Mexico, Turkey, Australia, Greece, Norway, Sweden, Peru, Romania, Argentina, United Kingdom
Mannkind Corporation

Completed

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Brazil, Spain, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, Ukraine, Czech Republic

Clinical Trials on Glucose Infusion in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations